pembrolizumab,ENB-003
merck
['pembro']
#cedarssinaicancer at #aacr23. dr. omid hamid is co-author on the poster enb-003, an etbr antagonist, in combination with #pembrolizumab for advanced solid #tumor: the enbolden trial presented at 10:30am pt. 
Cedars-Sinai Cancer, ranked #9 in the nation in 2021 by U.S. News & World Report.